{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:02:14Z","timestamp":1785495734600,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"DOI":"10.7759\/cureus.113714","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:55:22Z","timestamp":1785495322000},"source":"Crossref","is-referenced-by-count":0,"title":["Utility of GATA3, Uroplakin-II, and p40 Markers in the Diagnosis of Urothelial Carcinoma"],"prefix":"10.7759","author":[{"given":"Lavanya","family":"Manjari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrutha","family":"M R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"K R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"P O","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"H","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-263. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto GJ","year":"2022","unstructured":"Netto GJ, Amin MB, Berney DM, et al.. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors. Eur Urol. 2022, 82:469-482. 10.1016\/j.eururo.2022.07.002","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59081452","article-title":"Diagnostic and prognostic roles of GATA3 immunohistochemistry in urothelial carcinoma","volume":"59","author":"Yoo D","year":"2023","unstructured":"Yoo D, Min KW, Pyo JS, Kim NY. Diagnostic and prognostic roles of GATA3 immunohistochemistry in urothelial carcinoma. Medicina (Kaunas). 2023, 59:1452. 10.3390\/medicina59081452","journal-title":"Medicina (Kaunas)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182a0218f","article-title":"GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors","volume":"38","author":"Miettinen M","year":"2014","unstructured":"Miettinen M, McCue PA, Sarlomo-Rikala M, et al.. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014, 38:13-22. 10.1097\/PAS.0b013e3182a0218f","journal-title":"Am J Surg Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000143","article-title":"Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma","volume":"23","author":"Hoang LL","year":"2015","unstructured":"Hoang LL, Tacha D, Bremer RE, Haas TS, Cheng L. Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma. Appl Immunohistochem Mol Morphol. 2015, 23:711-716. 10.1097\/PAI.0000000000000143","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.04.015","article-title":"The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma","volume":"45","author":"Lin X","year":"2014","unstructured":"Lin X, Zhu B, Villa C, Zhong M, Kundu S, Rohan SM, Yang XJ. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma. Hum Pathol. 2014, 45:1824-1829. 10.1016\/j.humpath.2014.04.015","journal-title":"Hum Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2016.05.008","article-title":"A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma","volume":"48","author":"Leivo MZ","year":"2016","unstructured":"Leivo MZ, Elson PJ, Tacha DE, Delahunt B, Hansel DE. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Pathology. 2016, 48:543-549. 10.1016\/j.pathol.2016.05.008","journal-title":"Pathology"},{"key":"ref8","article-title":"Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants","volume":"22","author":"Warrick JI","year":"201912022","unstructured":"Warrick JI, Sj\u00f6dahl G, Kaag M, et al.. Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. European Urology [Internet. 201912022, 22:18-22.","journal-title":"European Urology [Internet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0329-RA","article-title":"Bladder cancer in the genomic era","volume":"143","author":"Guo CC","year":"2019","unstructured":"Guo CC, Czerniak B. Bladder cancer in the genomic era. Arch Pathol Lab Med. 2019, 143:695-704. 10.5858\/arpa.2018-0329-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040100","article-title":"Bladder cancer: New insights into its molecular pathology","volume":"10","author":"Inamura K","year":"2018","unstructured":"Inamura K. Bladder cancer: New insights into its molecular pathology. Cancers (Basel). 2018, 10:100. 10.3390\/cancers10040100","journal-title":"Cancers (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.158","article-title":"Update for the practicing pathologist: The International Consultation on Urologic Disease-European Association of Urology consultation on bladder cancer","volume":"28","author":"Amin MB","year":"2015","unstructured":"Amin MB, Smith SC, Reuter VE, et al.. Update for the practicing pathologist: The International Consultation on Urologic Disease-European Association of Urology consultation on bladder cancer. Mod Pathol. 2015, 28:612-630. 10.1038\/modpathol.2014.158","journal-title":"Mod Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/his.15559","article-title":"Grading of bladder cancer: updates, controversies and practical solutions","volume":"88","author":"Downes MR","year":"2026","unstructured":"Downes MR, van der Kwast TH, Lopez-Beltran A, Cheng L. Grading of bladder cancer: updates, controversies and practical solutions. Histopathology. 2026, 88:86-107. 10.1111\/his.15559","journal-title":"Histopathology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2022.8282","article-title":"Diagnostic value of GATA3 and uroplakin 3 in differentiating urothelial carcinoma from prostatic and colorectal carcinoma","volume":"28","author":"Salama M","year":"2022","unstructured":"Salama M, Khairy DA. Diagnostic value of GATA3 and uroplakin 3 in differentiating urothelial carcinoma from prostatic and colorectal carcinoma. Open Access Maced J Med Sci. 2022, 28:514-518. 10.3889\/oamjms.2022.8282","journal-title":"Open Access Maced J Med Sci"},{"key":"ref14","article-title":"The immunoreactivity of uroplakin III in urothelial carcinoma of urinary bladder and other non-urothelial carcinoma","volume":"19","author":"Naji AZ","year":"2019","unstructured":"Naji AZ, Mahdi AE, Kerbel HA. The immunoreactivity of uroplakin III in urothelial carcinoma of urinary bladder and other non-urothelial carcinoma. Med-Leg Update. 2019, 19:319.","journal-title":"Med-Leg Update"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.15218\/zjms.2024.36","article-title":"Immunohistochemical expression of GATA3 in urothelial carcinoma of urinary bladder","volume":"28","author":"Abdulkhaliq S","year":"2024","unstructured":"Abdulkhaliq S, A. Jalal J. Immunohistochemical expression of GATA3 in urothelial carcinoma of urinary bladder. Zanco J Med Sci. 2024, 28:377-385. 10.15218\/zjms.2024.36","journal-title":"Zanco J Med Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/IJPM.IJPM_228_18","article-title":"Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma","volume":"62","author":"Agarwal H","year":"2019","unstructured":"Agarwal H, Babu S, Rana C, et al.. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol. 2019, 62:244-250. 10.4103\/IJPM.IJPM_228_18","journal-title":"Indian J Pathol Microbiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0085-OA","article-title":"Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition","volume":"140","author":"Sanfrancesco J","year":"2016","unstructured":"Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P, Hansel DE. Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition. Arch Pathol Lab Med. 2016, 140:543-551. 10.5858\/arpa.2015-0085-OA","journal-title":"Arch Pathol Lab Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi W","year":"2014","unstructured":"Choi W, Porten S, Kim S, et al.. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014, 25:152-165. 10.1016\/j.ccr.2014.01.009","journal-title":"Cancer Cell"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318260cde7","article-title":"Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung","volume":"36","author":"Chang A","year":"2012","unstructured":"Chang A, Amin A, Gabrielson E, Illei P, Roden RB, Sharma R, Epstein JI. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012, 36:1472-1476. 10.1097\/PAS.0b013e318260cde7","journal-title":"Am J Surg Pathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31802f5d33","article-title":"Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma","volume":"31","author":"Chuang AY","year":"2007","unstructured":"Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007, 31:1246-1255. 10.1097\/PAS.0b013e31802f5d33","journal-title":"Am J Surg Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/509780-utility-of-gata3-uroplakin-ii-and-p40-markers-in-the-diagnosis-of-urothelial-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:55:23Z","timestamp":1785495323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/509780-utility-of-gata3-uroplakin-ii-and-p40-markers-in-the-diagnosis-of-urothelial-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.113714","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,31]]}}}